Although C5 inhibitors can effectively alleviate intravascular hemolysis, they do not affect extravascular hemolysis mediated by the complement protein C3d, resulting in incomplete response and persistent symptoms in some patients with PNH. This evidence concerns the gene C5 and paroxysmal nocturnal hemoglobinuria.